Apixaban and Limiting Aspirin for Patients With Atrial Fibrillation, Percutaneous Coronary Intervention, And Multimorbidity

Overview

Journal JACC Adv

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 4

PMID 39493312

Authors

Konstantin A Krychtiuk

Renato D Lopes

Daniel M Wojdyla

Shaun G Goodman

Ronald Aronson

Stephan Windecker

Roxana Mehran

Christopher B Granger

John H Alexander

Karen P Alexander

Affiliations

Soon will be listed here.

Abstract

Background: Patients with atrial fibrillation (AF) after an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) with multiple comorbidities are at increased risk for bleeding and ischemic events.

Objectives: This post-hoc analysis of AUGUSTUS describes the safety and efficacy of antithrombotic regimens in patients with multimorbidity.

Methods: AUGUSTUS was a 2 × 2 factorial, randomized controlled trial evaluating the safety of apixaban vs vitamin K antagonists (VKA) (open-label) and aspirin vs placebo (double-blind) in patients with AF and ACS and/or PCI treated with a P2Y inhibitor. Patients were categorized as having no multimorbidity (0-2 comorbidities), moderate multimorbidity (3-4 comorbidities), or high multimorbidity (≥5 comorbidities). The associations between multimorbidity and clinical outcomes and interactions with antithrombotic regimens were tested.

Results: Of 4,493 patients (97.4%) with available comorbidity data, 1,897 (42.2%) had no multimorbidity, 2,110 (47%) had moderate, and 486 (10.8%) had high multimorbidity. Patients with moderate (HR: 1.23; 95% CI: 1.02-1.47) and high (HR: 1.98; 95% CI: 1.55-2.54) multimorbidity had higher rates of International Society on Thrombosis and Haemostasis (ISTH) major or clinically relevant nonmajor (CRNM) bleeding compared to patients with no multimorbidity. No significant interaction between multimorbidity and apixaban vs vitamin K antagonists was observed for ISTH major bleeding/CRNM ( = 0.415), death or hospitalization ( = 0.092), or death or ischemic event ( = 0.299). Similarly, no significant interaction between multimorbidity and aspirin vs placebo was seen for ISTH major bleeding/CRNM ( = 0.261), death or hospitalization ( = 0.646), or death or ischemic event ( = 0.608).

Conclusions: Our findings support the standard use of apixaban plus a P2Y inhibitor in patients with AF and ACS/PCI, irrespective of the presence of multimorbidity.

References

Piccini J, Hellkamp A, Washam J, Becker R, Breithardt G, Berkowitz S . Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2015; 133(4):352-60. DOI: 10.1161/CIRCULATIONAHA.115.018544. View

Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M . Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011; 6(9):e24964. PMC: 3177852. DOI: 10.1371/journal.pone.0024964. View

Ten Berg J, Steg P, Bhatt D, Hohnloser S, de Veer A, Nordaby M . Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After.... Am J Cardiol. 2020; 125(5):735-743. DOI: 10.1016/j.amjcard.2019.11.029. View

Alexander K, Brouwer M, Mulder H, Vinereanu D, Lopes R, Proietti M . Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2018; 208:123-131. DOI: 10.1016/j.ahj.2018.09.017. View

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

Focks J, Brouwer M, Wojdyla D, Thomas L, Lopes R, Washam J . Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016; 353:i2868. PMC: 4908974. DOI: 10.1136/bmj.i2868. View

Lawton J, Tamis-Holland J, Bangalore S, Bates E, Beckie T, Bischoff J . 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021; 79(2):e21-e129. DOI: 10.1016/j.jacc.2021.09.006. View

Gencer B, Eisen A, Berger D, Nordio F, Murphy S, Grip L . Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. Am Heart J. 2022; 247:24-32. DOI: 10.1016/j.ahj.2021.12.017. View

Joosten L, van Doorn S, van de Ven P, Kohlen B, Nierman M, Koek H . Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2023; 149(4):279-289. DOI: 10.1161/CIRCULATIONAHA.123.066485. View

10.

Volgman A, Nair G, Lyubarova R, Merchant F, Mason P, Curtis A . Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022; 79(2):166-179. DOI: 10.1016/j.jacc.2021.10.037. View

11.

van Rein N, Heide-Jorgensen U, Lijfering W, Dekkers O, Sorensen H, Cannegieter S . Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation. 2018; 139(6):775-786. DOI: 10.1161/CIRCULATIONAHA.118.036248. View

12.

Carnicelli A, Hong H, Connolly S, Eikelboom J, Giugliano R, Morrow D . Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022; 145(4):242-255. PMC: 8800560. DOI: 10.1161/CIRCULATIONAHA.121.056355. View

13.

Clegg A, Young J, Iliffe S, Rikkert M, Rockwood K . Frailty in elderly people. Lancet. 2013; 381(9868):752-62. PMC: 4098658. DOI: 10.1016/S0140-6736(12)62167-9. View

14.

Chamberlain A, Alonso A, Gersh B, Manemann S, Killian J, Weston S . Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study. Am Heart J. 2017; 185:74-84. PMC: 5343767. DOI: 10.1016/j.ahj.2016.11.008. View

15.

Maeng M, Steg P, Bhatt D, Hohnloser S, Nordaby M, Miede C . Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. JACC Cardiovasc Interv. 2019; 12(23):2346-2355. DOI: 10.1016/j.jcin.2019.07.059. View

16.

Hijazi Z, Alexander J, Li Z, Wojdyla D, Mehran R, Granger C . Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2021; 143(12):1215-1223. DOI: 10.1161/CIRCULATIONAHA.120.051020. View

17.

Lopes R, Hong H, Harskamp R, Bhatt D, Mehran R, Cannon C . Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol. 2020; 5(5):582-589. PMC: 7240352. DOI: 10.1001/jamacardio.2019.6175. View

18.

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

19.

Lopes R, Vora A, Liaw D, Granger C, Darius H, Goodman S . An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary.... Am Heart J. 2018; 200:17-23. DOI: 10.1016/j.ahj.2018.03.001. View

20.

Sullivan A, Nanna M, Rao S, Cantrell S, Gibson C, Verheugt F . A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019; 96(2):E102-E109. PMC: 7211549. DOI: 10.1002/ccd.28535. View